Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688934 · ClinicalTrials.gov registry record · Phase 2
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee
A Phase 2 study, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
NCT01688934 is a Phase 2 study that has completed, run by Purdue Pharma. The registered enrollment target is 230 participants.
The verdict
NCT01688934, a Phase 2 study, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.
Interventions
- DRUG Placebo
- DRUG V116517 50-mg tablets
- DRUG V116517 30-mg tablets
- DRUG Naproxen 500-mg capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01688934
The ClinicalTrials.gov registry entry for NCT01688934 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01688934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01688934 about?
NCT01688934 is a clinical study titled "Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee". The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.
What is the current status of trial NCT01688934?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2012-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01688934?
The interventions under investigation include: Placebo (DRUG), V116517 50-mg tablets (DRUG), V116517 30-mg tablets (DRUG), Naproxen 500-mg capsules (DRUG).
Who is sponsoring clinical trial NCT01688934?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.